Heron Therapeutics, INC /DE/ 8-K filings

Heron Therapeutics, Inc. has amended its Tax Benefit Preservation Plan, extending the final expiration date by three years to August 14, 2029.

Heron Therapeutics announced Q2 2026 results with mixed revenue performance, withdrew full-year financial guidance, and is exploring strategic alternatives.

Heron Therapeutics has been notified by Nasdaq that its common stock failed to maintain the minimum $1.00 bid price requirement.

Heron Therapeutics held its 2026 Annual Meeting of Stockholders, with key proposals including director elections, auditor ratification, executive compensation, and equity plan amendments receiving stockholder approval.

Heron Therapeutics announced a U.S. District Court ruling invalidating key patents for its CINVANTI drug, with the company planning to appeal the decision.

Heron Therapeutics announced first quarter 2026 financial results, reporting $34.7 million in net revenue and reaffirming full-year guidance, driven by significant growth in its Acute Care franchise.

Heron Therapeutics has amended employment and retention agreements for its CEO and key executives to update severance, change-in-control, and restrictive covenant terms.

Heron Therapeutics announced strong Q4 and full-year 2025 financial results, driven by significant revenue growth in its Acute Care franchise and optimistic 2026 guidance.

Heron Therapeutics announced preliminary, unaudited net revenue of approximately $40.5 million for Q4 2025 and $154.9 million for full-year 2025, driven by ZYNRELEF's significant growth.

Heron Therapeutics announced strong Q3 2025 revenue growth for its Acute Care franchise, driven by ZYNRELEF and APONVIE, while reaffirming full-year financial guidance.

Heron Therapeutics announced the appointment of Thomas Cusack to its Board of Directors, stemming from a cooperation agreement with Rubric Capital Management LP.

Heron Therapeutics stockholders approved proposals allowing for the issuance of common stock upon conversion of convertible notes and preferred stock, potentially exceeding 19.99% of outstanding shares.

Heron Therapeutics, Inc. has entered into a new office lease agreement for its corporate headquarters in Cary, North Carolina, for a term of approximately 111 months.

Heron Therapeutics' Board of Directors adopted a Tax Benefit Preservation Plan to safeguard its substantial net operating losses from potential ownership changes.

Heron Therapeutics successfully refinanced existing debt and raised new capital through a series of agreements, including convertible notes, a private placement, and an expanded credit facility.

Heron Therapeutics has entered a new Framework Agreement with Patheon and Thermo Fisher Scientific for the manufacturing and supply of products, committing to purchase 38,400 kg through 2026.

Heron Therapeutics announced a comprehensive capital restructuring, reducing total debt by $30 million, extending maturities to 2030, and reported improved Q2 2025 financial results with raised Adjusted EBITDA guidance.

Heron Therapeutics, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where all four proposals, including the re-election of six directors and the ratification of its independent auditor, were approved.

Heron Therapeutics announces positive Q1 2025 financial results, including record adjusted EBITDA and increased full-year guidance, alongside a settlement in patent litigation.

Heron Therapeutics settles patent disputes with Mylan, allowing Mylan to market generic versions of CINVANTI and APONVIE starting in June 2032.

Heron Therapeutics announced the appointment of Mark Hensley as its new Chief Operating Officer, effective April 28, 2025.

Heron Therapeutics announces positive Q4 2024 results, driven by strong revenue growth and strategic corporate updates.

Heron Therapeutics amends its Working Capital Facility Agreement with Hercules Capital, extending the maturity date to potentially September 1, 2027, depending on the status of its convertible senior notes.

Heron Therapeutics has announced the relocation of its corporate headquarters from San Diego, California to Cary, North Carolina, effective January 1, 2025.

Heron Therapeutics secured a favorable ruling in its patent infringement lawsuit against Fresenius Kabi, preventing the launch of a generic version of CINVANTI until 2035.

Heron Therapeutics announced positive year-to-date adjusted EBITDA and narrowed its full-year 2024 financial guidance, driven by revenue growth and financial management.

Heron Therapeutics has appointed Michael Kaseta, a seasoned finance and biopharma executive, to its Board of Directors.

Heron Therapeutics announced its second quarter 2024 financial results, highlighted by increased product sales and narrowed financial guidance.

Heron Therapeutics announced the FDA has accepted their application for a new vial access needle for ZYNRELEF, with a PDUFA goal date set for September 23, 2024.

Heron Therapeutics' stockholders approved an increase in authorized common stock shares and amendments to equity incentive and employee stock purchase plans at the 2024 Annual Meeting.